A phase Ill trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)
A phase Ill trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)
저자
Toi, M.; Lee, S-J; Lee, E. S.; Ohtani, S.; Im, Y-H; Im, S-A; Park, B-W; Kim, S-B; Yanagita, Y.; Takao, S.; Ohno, S.; Aogi, K.; Iwata, H.; Kim, A.; Sasano, H.; Yokota, I.; Ohashi, Y.; Masuda, N.